Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00905021 · ClinicalTrials.gov registry record · Phase 1
Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer
A Phase 1 study, sponsored by Baylor Breast Care Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00905021 is a Phase 1 study that was terminated before completion, run by Baylor Breast Care Center. The registered enrollment target is 4 participants.
The verdict
NCT00905021, a Phase 1 study, was terminated before completion, sponsored by Baylor Breast Care Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The investigators want to find out if the treatments used in this study are helpful to patients that are diagnosed with hormone receptor positive metastatic breast cancer. The investigators want to also look at any side effects that could happen while patients are on the study treatments. The investigators want to see if there are any changes that could show us if your cancer is responding to the study treatments.
Interventions
- DRUG Exemestane
- DRUG Sutent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00905021
The ClinicalTrials.gov registry entry for NCT00905021 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Breast Care Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exemestane is the first listed.
NCT00905021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00905021 about?
NCT00905021 is a clinical study titled "Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer". The investigators want to find out if the treatments used in this study are helpful to patients that are diagnosed with hormone receptor positive metastatic breast cancer. The investigators want to also look at any side effects that could happen while patients are on the study treatments. The invest...
What is the current status of trial NCT00905021?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2010-03. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00905021?
The interventions under investigation include: Exemestane (DRUG), Sutent (DRUG).
Who is sponsoring clinical trial NCT00905021?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.